Natera Launches Competitor Rare Disease Detection Product, GeneDx Stock Price Declines

2026-03-12 18:47:56

Investing.com – GeneDx Holdings Corp (NASDAQ:WGS) stock fell 7.8% on Thursday after Natera announced the commercial launch of Zenith Genomics, a whole genome sequencing test product for rare disease diagnosis.

Natera Inc (NASDAQ:NTRA) announced the launch of Zenith Genomics, aimed at improving detection of rare genetic diseases. The test combines whole genome sequencing with long-read sequencing confirmation technology, capable of detecting features such as tandem repeat expansions, providing comprehensive diagnostic analysis for rare and ultra-rare diseases.

The technology was developed by MyOme, and through an exclusive partnership with Natera, the company will distribute the test across the United States. Natera will showcase the Zenith platform and its performance at the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Baltimore, Maryland.

Rare diseases affect approximately 30 million Americans each year, with patients typically experiencing 4-7 years of diagnostic delays. In 2019, the cumulative economic burden of rare diseases in the U.S. was nearly $997 billion, including $449 billion in direct medical costs and $548 billion in indirect and non-medical expenses.

GeneDx may also face pressure from insider selling. CEO Katherine Stueland sold 3,678 shares at an average price of $86.748 on Sunday to cover tax withholding obligations related to restricted stock units. CFO Kevin Feeley sold 1,280 shares at an average price of $86.754 on Sunday, also to meet tax withholding obligations from restricted stock units.

After the sales, Stueland beneficially owns 44,955 shares of Class A common stock, along with restricted stock units representing up to 445,366 shares and 107,610 stock options. Feeley owns 21,842 shares, as well as 120,435 restricted stock units and 25,906 stock options.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes